NASDAQ:AURA Aura Biosciences Q3 2026 Earnings Date & Estimates $6.30 -0.16 (-2.48%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$6.28 -0.02 (-0.38%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aura Biosciences is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 11, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 11, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Aura Biosciences in Q3 2026Aura Biosciences is expected to post earnings of -$0.3681 per share. In the same quarter a year earlier Aura Biosciences reported -$0.40 per share. Aura Biosciences last reported on August 11, 2026, posting -$0.48 per share and missing the -$0.3750 consensus estimate. Aura Biosciences has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.3681Prior-Year EPS-$0.40Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.48 (Missed by -$0.1050)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Aura Biosciences Q3 2026 Earnings FAQ When does Aura Biosciences report Q3 2026 earnings? Aura Biosciences (NASDAQ:AURA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Aura Biosciences' Q3 2026 earnings call? Aura Biosciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Aura Biosciences? Analysts expect Aura Biosciences to post earnings of -$0.3681 per share for Q3 2026. Aura Biosciences Earnings HeadlinesAura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry IndexSeptember 21, 2026 | marketscreener.comMAura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.October 25 at 1:00 AM | Profits Run (Ad)Aura Biosciences to Participate in Upcoming Investor ConferenceSeptember 2, 2026 | globenewswire.comAura Biosciences Grants Inducement Equity Awards to Newly Appointed ExecutivesSeptember 1, 2026 | quiverquant.comQAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA) (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue. Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer. AU-011 is administered by intravitreal injection and is designed to target tumor cells in the eye before activating a light-based treatment intended to destroy them. The company is also advancing additional candidates based on its tumor-targeting technology for other solid tumors. Founded in 2009 and headquartered in the United States, Aura Biosciences conducts research and clinical development activities through collaborations and clinical programs in the U.S. and other regions. The company was founded and is led by Elisabet de los Pinos, who serves as president and chief executive officer.View Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real StoryLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
